Clinical trial · no report yet · Phase 2
NCT04165772
Study of Induction PD-1 Blockade in Subjects With Locally Advanced Mismatch Repair Deficient Solid Tumors
- NCT04165772 ↗
- Recruiting
- Memorial Sloan Kettering Cancer Center
- 3 commentary sources found
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built. Commentary is thin so far, so the report would be short.
| Channel | Found | |
|---|---|---|
| YouTube | 1 | |
| Podcasts | 1 | |
| X threads | 1 |
The trial
ClinicalTrials.gov- Official title
- A Phase II Study of Induction PD-1 Blockade in Subjects With Locally Advanced Mismatch Repair Deficient Solid Tumors
- Phase
- Phase 2
- Status
- Recruiting
- Conditions
- Rectal Adenocarcinoma; Clinical Stage: Stage II (T3-4, N-); Stage III (Any T, N+); Solid Tumor; Solid Tumor, Adult
- Interventions
- TSR-042 or Dostarlimab; capecitabine or 5-FU; Intensity Modulated Radiation Therapy (IMRT)
- Arms
- Cohort 1 · Experimental
- Cohort 2 · Other
- Cohort 3 · Other
- Enrollment
- 212 (estimated)
- Primary outcomes
- Pathologic complete response (pCR) or complete clinical response (cCR) at 12 months
- Sponsor
- Memorial Sloan Kettering Cancer Center with Tesaro, Inc.
- Start
- Dec 11, 2019
- Primary completion
- Nov 30, 2026 (estimated)
- Results posted
- No
- Registry record
- NCT04165772 · updated Sep 15, 2026
Publications
linked from the registry- Cercek A, Foote MB, Rousseau B, Smith JJ, Shia J, Sinopoli J, Weiss J, Lumish M, Temple L, Patel M, Wilde C, Saltz LB, Argiles G, Stadler Z, Artz O, Maron S, Ku G, Gu P, Janjigian YY, Molena D, Iyer G, Coleman J, Abida W, Cohen S, Soares K, Schattner M, Strong VE, Yaeger R, Paty P, Shcherba M, Sugarman R, Romesser PB, Zervoudakis A, Desai A, Segal NH, El Dika I, Widmar M, Wei I, Pappou E, Fumo G, Aparo S, Gonen M, Gollub M, Jayaprakasam VS, Kim TH, Garcia Aguilar J, Weiser M, Diaz LA Jr. Nonoperative Management of Mismatch Repair-Deficient Tumors. N Engl J Med. 2025 Jun 19;392(23):2297-2308. doi: 10.1056/NEJMoa2404512. Epub 2025 Apr 27. PubMed 40293177
- Saude-Conde R, Nguyen D, Hendlisz A. Immunotherapies in non-metastatic gastrointestinal cancers. Curr Opin Oncol. 2023 Jul 1;35(4):334-346. doi: 10.1097/CCO.0000000000000956. Epub 2023 May 9. PubMed 37222204
- Costa B, Vale N. Dostarlimab: A Review. Biomolecules. 2022 Jul 26;12(8):1031. doi: 10.3390/biom12081031. PubMed 35892341
- Cercek A, Lumish M, Sinopoli J, Weiss J, Shia J, Lamendola-Essel M, El Dika IH, Segal N, Shcherba M, Sugarman R, Stadler Z, Yaeger R, Smith JJ, Rousseau B, Argiles G, Patel M, Desai A, Saltz LB, Widmar M, Iyer K, Zhang J, Gianino N, Crane C, Romesser PB, Pappou EP, Paty P, Garcia-Aguilar J, Gonen M, Gollub M, Weiser MR, Schalper KA, Diaz LA Jr. PD-1 Blockade in Mismatch Repair-Deficient, Locally Advanced Rectal Cancer. N Engl J Med. 2022 Jun 23;386(25):2363-2376. doi: 10.1056/NEJMoa2201445. Epub 2022 Jun 5. PubMed 35660797